Superworth

Cryo Cell International EV/EBIT CCEL

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2013.

Today, Nov 2, 2026
11.1×
10-year median
10.9×
Against its 10-year history
52nd
percentile: 0 is its lowest day, 100 its highest
10-year range
5.1× to 18.1×
Peer median
7.8×

Cryo Cell International's EV/EBIT is 11.1× as of Nov 2, 2026.

That is above its ten-year median of 10.9×, close to the middle of its last ten years.

Over that time it ranged from 5.1× in Oct 2020 to 18.1× in Mar 2025.

The median for 10 healthcare stocks of a similar size is 7.8×.

EV/EBIT over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far11.1×6.3×11.1×
20257.7×7.7×18.1×
202411.2×11.2×13.0×
202312.9×8.1×16.2×
202215.0×8.2×17.8×
202111.3×5.2×13.2×
20205.9×5.1×8.1×
20197.4×7.4×12.9×
201812.1×9.2×15.0×
201715.0×10.0×15.0×
201613.0×7.9×13.0×
201510.5×9.0×17.0×
201411.8×8.9×21.7×
201317.3×17.1×46.4×

Against its peers

Companies in Healthcare nearest Cryo Cell International's size, closest first, today.

Where Cryo Cell International ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Cryo Cell International

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.